NCT06489808View on ClinicalTrials.gov

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

May 31, 2027

Conditions
Relapsed/Refractory Large B-Cell Lymphoma
Interventions
DRUG

Linperlisib

Linperlisib RP2D D1-14

DRUG

Rituximab

rituximab 375 mg/m2 D0

DRUG

Gemcitabine

gemcitabine per regimen dosage

DRUG

Oxaliplatin

Oxaliplatin 130 mg/m2 D1

DRUG

Ifosfamide

Ifosfamide 5g/m2 D2

DRUG

Carboplatin

Carboplatin AUC=5mg/mL · min (maximum absolute dose/cycle = 800 mg)

DRUG

Etoposide

Etoposide 100mg/m2 D1-3

DRUG

Dexamethasone

Dexamethasone 40mg D1-4

DRUG

Cisplatin

Cisplatin 100mg/m2 D1, continuous intravenous infusion

DRUG

Ara-C

Ara-C 2g/m2 q12h D2

DRUG

Vinorelbine

Vinorelbine 20mg/m2 D1

DRUG

Mitoxantrone hydrochloride liposome

Mitoxantrone hydrochloride liposome 18mg/m2 D1

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Disease Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER